Medication info
Donghwa Rosuvastatin 5 mg Tablet (Rosuvastatin Calcium)

Donghwa Rosuvastatin 5 mg Tablet (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Donghwa Pharmaceutical Co., Ltd.
Appearance
Yellow, round, film-coated tablets
Packaging
30 tablets/PTP [15 tablets/PTP X 2]
Approval status
Active

MFDS item code 202002282 · Approved 2020.04.01 · Insurance code 642706870

Summary

Main use
Improvement of dyslipidemia, reduction of cardiovascular disease risk, inhibition of atherosclerosis progression
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary for patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
Ages 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. Doses should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Donghwa Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, reduction of cardiovascular disease risk, inhibition of atherosclerosis progression

  • Primary hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary artery disease
  • stroke risk
View approved original text

This medication is used as an adjunct when diet and exercise do not adequately control primary hypercholesterolemia or mixed dyslipidemia. It also supplements dietary therapy or other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia. This drug lowers total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis. In children aged 10 to 17 with heterozygous familial hypercholesterolemia meeting specific criteria, it is also used as an adjunct to dietary therapy. Additionally, it helps as an adjunct to dietary therapy in patients with primary dysbetalipoproteinemia. In adults at high risk for cardiovascular disease, it effectively reduces the risk of stroke, myocardial infarction, and arterial revascularization, thus decreasing cardiovascular disease risk. It is used for various hyperlipidemias and reduction of cardiovascular disease risk.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary for patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

Ages 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. Doses should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This drug should not be used in certain patients. For instance, those who are allergic to this medication, have active liver disease, suffer from myopathy, or have severe kidney dysfunction should not take this drug. Women who are pregnant, breastfeeding, or may become pregnant should consult their doctor before use. Additionally, individuals with a history of muscle disorders or moderate to severe kidney dysfunction should avoid high doses, and those with genetically sensitive conditions to lactose contained in this medication should also refrain from use. This drug can affect liver function, so patients with a history of liver disease or those who consume alcohol heavily should have liver function tests before and regularly during treatment. If symptoms of muscle pain or weakness occur, they should immediately inform their healthcare provider, and in severe cases, discontinuation of the drug may be necessary. This drug may interact with other medications, so any other medications being taken should be disclosed to healthcare providers. Especially, when used in combination with certain antiviral drugs, immunosuppressants, antifungal agents, and fibrate drugs, the risk of muscle-related side effects may increase. Pregnant and breastfeeding women should not take this medication, and women who may become pregnant should use appropriate contraceptive measures. In the case of overdose, there is no specific antidote, so immediate medical attention should be sought for proper treatment, and liver function and muscle enzyme levels should be monitored. Lastly, this medication may cause dizziness, so caution is advised when driving or operating machinery.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, shortness of breath, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and acute generalized exanthematous pustulosis, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, sensory disturbances, chest discomfort, loss of appetite, abdominal distension, syncope, systemic pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is important to keep the storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow, round, film-coated tablets

Package unit

30 tablets/PTP [15 tablets/PTP X 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.